Table 3.

Median Time to Progression and 2-Year Overall Survival by Risk Group Among Patients Presenting with de novo Stage IV Disease

	Low risk (RS < 18)	Intermediate risk (RS 18–30)	High risk (RS ≥ 31)	Log rank, p
	Median TTP, months
All patients (n = 101)	NR (16–NR)	22 (16–NR)	16 (9–25)	0.010
ER positive (n = 85)	32 (16–NR)	22 (16–NR)	15 (9–25)	0.007
ER positive/HER2 negative (n = 69)	NR (16–NR)	20 (16–NR)	15 (8–27)	0.003
	2-Year overall survival, %
All patients (n = 101)	100 (78–100)	100 (78–100)	80 (69–93)	0.035
ER positive (n = 85)	100 (78–100)	100 (78–100)	77 (64–94)	0.008
ER positive/HER2 negative (n = 69)	100 (78–100)	100 (75–100)	69 (51–93)	< 0.001

Abbreviations: RS, recurrence score; NR, not reached; ER, estrogen receptor.